June 7, 2012

Catalyst Pharmaceutical Partners to Present CPP-115 Progress at the 2012 College on Problems of Drug Dependence Symposium

CORAL GABLES, Fla., June 7, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that Steven R. Miller, Ph.D., Catalyst's Chief Operating Officer and Chief Scientific Officer, will present "CPP-115: A Second-Generation GABA Aminotransferase Inhibitor" during a symposium at the 74th Annual Meeting of the College on Problems of Drug Dependence (CPDD), which is being held at the La Quinta Resort and Club in Palm Springs, California on June 9th through June 14th.

Dr. Miller's presentation will be given on Tuesday, June 12th as part of a symposium entitled, "Recent Advances in Medication Development for the Treatment of Substance Abuse Disorders". The Chair of the symposium will be David J. McCann, Ph.D., Associate Director, NIDA Division of Pharmacotherapies and Medical Consequences of Drug Abuse. Dr. Miller's presentation materials will be posted on June 12th at www.catalystpharma.com under "Events & Presentations" in the "Investors" section.

About CPP-115

CPP-115 is a novel GABA aminotransferase inhibitor and vigabatrin analogue that, based on preclinical studies to-date, is greater than 100 times more potent than vigabatrin and may have reduced side effects (e.g., visual field defects, or VFDs and sedation) from those associated with vigabatrin. Catalyst licensed CPP-115 from Northwestern University where it was invented by Dr. Richard B. Silverman, the John Evans Professor of Chemistry, and a team of scientists. Dr. Silverman holds more than 40 patents and is the inventor of Pfizer's drug, pregabalin (Lyrica®). CPP-115 has been granted Orphan Drug Designation for the treatment of infantile spasms by the U.S. Food & Drug Administration (FDA), and has been granted Orphan Medicinal Product Designation for the treatment of West Syndrome by the European Commission. It has also been granted Fast Track status by the FDA for the treatment of cocaine addiction. CPP-115 has successfully completed its initial Phase I(a), first-in-man, single ascending dose safety and tolerance study. Catalyst is planning to develop CPP-115 for several indications, including addiction, epilepsy and other CNS indications.

About Catalyst Pharmaceutical Partners, Inc.

Catalyst Pharmaceutical Partners, Inc. is a development-stage specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases and disorders of the central nervous system, including addiction and epilepsy. Catalyst has two products in development, CPP-109 and CPP-115, and is currently evaluating its lead product and first-in-class GABA aminotransferase inhibitor candidate, CPP-109, for the treatment of cocaine addiction. CPP-109 has been granted Fast Track status by the FDA for the treatment of cocaine addiction. Catalyst also plans to evaluate CPP-109 for the treatment of other addictions. Catalyst believes that it controls all current intellectual property for drugs that have a mechanism of action related to the inhibition of GABA aminotransferase. For more information about Catalyst, go to www.catalystpharma.com.

Forward Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including whether CPP-115 will be determined to be safe for use in humans, whether CPP-115 will be effective for the treatment of addiction, epilepsy or other CNS indications, whether CPP-109 or CPP-115 will ever be approved for commercialization, and those other factors described in the Company's filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC, may be found on the Company's website or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.

CONTACT: Patrick J. McEnany

Catalyst Pharmaceutical Partners

Chief Executive Officer

(305) 529-2522

pmcenany@catalystpharma.com

Melody Carey

Rx Communications Group

Co-President

(917) 322-2571

mcarey@rxir.com

Source: Catalyst Pharmaceutical Partners, Inc.